|
ARID1A wild-type
|
ovarian cancer
|
no benefit
|
GSK126
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, GSK126 had no significant effect on the growth of ovarian cancer cells with wild-type ARID1A in culture (PMID: 25686104).
|
25686104
|
|
ARID1A loss
|
Her2-receptor positive breast cancer
|
resistant
|
Trastuzumab
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to Herceptin (trastuzumab) in culture (PMID: 27172896).
|
27172896
|
|
ARID1A loss
|
Her2-receptor positive breast cancer
|
resistant
|
AZD8055
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to AZD8055 in culture (PMID: 27172896).
|
27172896
|
|
ARID1A loss
|
ovarian clear cell carcinoma
|
predicted - sensitive
|
JQ1
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, knockout of ARID1A in ovarian clear cell carcinoma cell lines resulted in increased sensitivity to growth inhibition by JQ1 compared to cells with wild-type ARID1A in culture (PMID: 29760405).
|
29760405
|
|
ARID1A loss
|
colorectal cancer
|
sensitive
|
Berzosertib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Berzosertib (VX-970) inhibited viability of a colorectal cancer cell line harboring ARID1A loss in culture (PMID: 29038346).
|
29038346
|
|
ARID1A loss
|
breast cancer
|
sensitive
|
AZD8055 + MK2206
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, breast cancer cells with loss of ARID1A demonstrated restored sensitivity to AZD8055 when additionally treated with MK2206 in culture (PMID: 27172896).
|
27172896
|
|
ARID1A loss
|
colon cancer
|
predicted - sensitive
|
unspecified PD-L1 antibody
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, ARID1A-deficient colon cancer xenograft models demonstrated an increased response to treatment with an anti-PD-L1 antibody compared to controls (PMID: 29736026).
|
29736026
|
|
ARID1A loss
|
ovarian cancer
|
predicted - sensitive
|
unspecified PD-L1 antibody
|
Preclinical |
Actionable |
In a preclinical study, an ARID1A-deficient orthotopic ovarian cancer mouse model treated with a PD-L1 antibody demonstrated improved survival and greater decreased tumor volume compared to those treated with control (PMID: 29736026).
|
29736026
|
|
ARID1A mutant
|
ovarian clear cell carcinoma
|
sensitive
|
Dasatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Sprycel (dasatinib) resulted in decreased cell growth of ovarian clear cell carcinoma (OCCC) cells harboring an ARID1A mutation in culture and anti-tumor activity in cell line xenograft models of OCCC (PMID: 27364904).
|
27364904
|
|
ARID1A mutant
|
renal cell carcinoma
|
predicted - sensitive
|
Bevacizumab + Everolimus
|
Case Reports/Case Series |
Actionable |
In a Phase II trial, 100% (7/7) of patients with papillary renal cell carcinoma (n=3) or unclassified renal cell carcinoma with papillary features (n=4) harboring ARID1A mutations achieved the primary endpoint of 6-month progression-free survival when treated with the combination of Afinitor (everolimus) and Avastin (bevacizumab) (PMID: 32975815; NCT01399918).
|
32975815
|
|
ARID1A mutant
|
bladder urothelial carcinoma
|
predicted - sensitive
|
Atezolizumab
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, metastatic urothelial carcinoma patients from the IMvigor210 trial harboring an ARID1A mutation (n=62) demonstrated a greater overall survival (15.4 mo vs 8.2 mo; P=0.03) compared to patients with wild-type ARID1A (n=213) when treated with Tecentriq (atezolizumab) (PMID: 32554706; NCT02108652).
|
32554706
|
|
ARID1A mutant
|
bladder urothelial carcinoma
|
predicted - sensitive
|
Nivolumab
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, metastatic urothelial carcinoma patients from the CheckMate275 trial harboring an ARID1A mutation (n=39) demonstrated a greater overall survival (11.4 mo vs 6.0 mo; P=0.03) compared to patients with wild-type ARID1A (n=100) when treated with Opdivo (nivolumab) (PMID: 32554706; NCT02387996).
|
32554706
|
|
ARID1A mutant
|
ovarian cancer
|
sensitive
|
UNC1999
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, UNC1999 inhibited growth of ovarian cancer cell lines harboring ARID1A mutations in culture (PMID: 25686104).
|
25686104
|
|
ARID1A mutant
|
ovarian clear cell carcinoma
|
sensitive
|
VE-821
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, ovarian clear cell carcinoma cells harboring an ARID1A mutation were sensitive to VE-821 in in vitro assays, demonstrating decreased cell survival (PMID: 27958275).
|
27958275
|
|
ARID1A mutant
|
ovarian clear cell carcinoma
|
sensitive
|
Berzosertib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Berzosertib (VX-970) treatment in ovarian clear cell carcinoma cells harboring an ARID1A mutation resulted in decreased cell survival and induction of DNA damage and apoptosis in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275).
|
27958275
|
|
ARID1A mutant
|
ovarian cancer
|
sensitive
|
GSK126
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, GSK126 selectively inhibited growth of ARID1A-mutant ovarian cancer cells in culture, and induced tumor regression in ARID1A-mutant ovarian cancer xenograft models (PMID: 25686104).
|
25686104
|
|
ARID1A mutant
|
endometrial cancer
|
predicted - sensitive
|
unspecified PD-1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in significantly longer median progression-free survival (4.6 vs 3.0 months, p=0.02) in patients with ARID1A-altered (n=10) endometrial cancer than in patients with ARID1A wild-type (n=13) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
melanoma
|
predicted - sensitive
|
unspecified PD-1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in longer median progression-free survival (45.4 vs 3.0 months, p=0.08) in patients with ARID1A-altered (n=6) melanoma than in patients with ARID1A wild-type (n=91) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
lung non-small cell carcinoma
|
predicted - sensitive
|
unspecified PD-1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in longer but not statistically significant median progression-free survival (8.7 vs 4.6 months, p=0.53) in patients with ARID1A-altered (n=7) non-small cell lung cancer than in patients with ARID1A wild-type (n=104) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
colorectal cancer
|
predicted - sensitive
|
unspecified PD-1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in significantly longer median progression-free survival (5.2 vs 2.1 months, p=0.005) in patients with ARID1A-altered (n=12) colorectal cancer than in patients with ARID1A wild-type (n=37) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
gastroesophageal cancer
|
predicted - sensitive
|
unspecified PD-1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in longer median progression-free survival (11.4 vs 2.5 months, p=0.21) in patients with ARID1A-altered (n=5) gastroesophageal cancer than in patients with ARID1A wild-type (n=16) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
Advanced Solid Tumor
|
predicted - sensitive
|
unspecified PD-1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in significantly longer median progression-free survival (PFS, 11 vs 4 months, p=0.006) in patients with ARID1A-altered (n=46) tumors than in patients with ARID1A wild-type (n=329) tumors, and improved overall survival (31 vs 20 months, p=0.13), ARID1A alterations predicted longer PFS (HR=0.61, p=0.02) after immune checkpoint inhibitor therapies independent of MSI or TMB status (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
endometrial cancer
|
predicted - sensitive
|
unspecified PD-L1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in significantly longer median progression-free survival (4.6 vs 3.0 months, p=0.02) in patients with ARID1A-altered (n=10) endometrial cancer than in patients with ARID1A wild-type (n=13) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
melanoma
|
predicted - sensitive
|
unspecified PD-L1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in longer median progression-free survival (45.4 vs 3.0 months, p=0.08) in patients with ARID1A-altered (n=6) melanoma than in patients with ARID1A wild-type (n=91) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
lung non-small cell carcinoma
|
predicted - sensitive
|
unspecified PD-L1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in longer but not statistically significant median progression-free survival (8.7 vs 4.6 months, p=0.53) in patients with ARID1A-altered (n=7) non-small cell lung cancer than in patients with ARID1A wild-type (n=104) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
colorectal cancer
|
predicted - sensitive
|
unspecified PD-L1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in significantly longer median progression-free survival (5.2 vs 2.1 months, p=0.005) in patients with ARID1A-altered (n=12) colorectal cancer than in patients with ARID1A wild-type (n=37) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
gastroesophageal cancer
|
predicted - sensitive
|
unspecified PD-L1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in longer median progression-free survival (11.4 vs 2.5 months, p=0.21) in patients with ARID1A-altered (n=5) gastroesophageal cancer than in patients with ARID1A wild-type (n=16) tumors (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
Advanced Solid Tumor
|
predicted - sensitive
|
unspecified PD-L1 antibody
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in significantly longer median progression-free survival (PFS, 11 vs 4 months, p=0.006) in patients with ARID1A-altered (n=46) tumors than in patients with ARID1A wild-type (n=329) tumors, and improved overall survival (31 vs 20 months, p=0.13), ARID1A alterations predicted longer PFS (HR=0.61, p=0.02) after immune checkpoint inhibitor therapies independent of MSI or TMB status (PMID: 32111729).
|
32111729
|
|
ARID1A mutant
|
stomach cancer
|
predicted - sensitive
|
M1774
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, M1774 inhibited tumor growth in a cell line xenograft model of gastric cancer harboring an ARID1A mutation (PMID: 38407317).
|
38407317
|
|
ARID1A mut PIK3CA act mut
|
ovarian cancer
|
sensitive
|
GSK126
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, expression of a constitutively active PIK3CA mutation in ARID1A-mutant ovarian cancer cell lines enhanced growth inhibition by GSK126 in culture (PMID: 25686104).
|
25686104
|
|
ARID1A inact mut
|
urinary bladder cancer
|
sensitive
|
Pictilisib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Pictilisib (GDC-0941) inhibited viability of bladder cancer cell lines harboring ARID1A inactivating mutations in culture (PMID: 35852858).
|
35852858
|
|
ARID1A inact mut
|
urinary bladder cancer
|
sensitive
|
Tazemetostat
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tazverik (tazemetostat) inhibited viability of bladder cancer cell lines harboring ARID1A inactivating mutations in culture (PMID: 35852858).
|
35852858
|
|
ARID1A inact mut
|
urinary bladder cancer
|
sensitive
|
CPI-1205
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, CPI-1205 inhibited viability of bladder cancer cell lines harboring ARID1A inactivating mutations in culture (PMID: 35852858).
|
35852858
|
|
ARID1A inact mut
|
urinary bladder cancer
|
sensitive
|
GSK126
|
Preclinical - Pdx & cell culture |
Actionable |
In a preclinical study, GSK126 inhibited cell viability in bladder cancer cell lines harboring ARID1A inactivating mutations in culture and inhibited tumor growth in patient-derived xenograft (PDX) and cell line xenograft models of bladder cancer harboring ARID1A inactivating mutations (PMID: 35852858).
|
35852858
|
|
ARID1A inact mut
|
female reproductive organ cancer
|
no benefit
|
PLX2853
|
Phase II |
Actionable |
In a Phase IIa trial, PLX2853 treatment demonstrated safety but failed to meet predetermined criteria for efficacy in patients with advanced gynecologic cancers harboring a pathogenic ARID1A mutation, resulting in a partial response in 7.1% (1/14, 1 patient with endometrial carcinoma) and stable disease in 35.7% (5/14) of evaluable patients (PMID: 37797273; NCT04493619).
|
37797273
|
|
ARID1A inact mut
|
endometrial cancer
|
sensitive
|
Tulmimetostat
|
Preclinical - Pdx |
Actionable |
In a preclinical study, Tulmimetostat inhibited tumor growth in endometrial cancer patient-derived xenograft (PDX) models harboring loss of function mutations in ARID1A (PMID: 38833522).
|
38833522
|
|
ARID1A inact mut
|
urinary bladder cancer
|
sensitive
|
Tulmimetostat
|
Preclinical - Pdx |
Actionable |
In a preclinical study, Tulmimetostat inhibited tumor growth in a bladder cancer patient-derived xenograft (PDX) model harboring a loss of function mutation in ARID1A (PMID: 38833522).
|
38833522
|
|
ARID1A inact mut
|
urinary bladder cancer
|
sensitive
|
MAK683
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, MAK683 inhibited viability of bladder cancer cell lines harboring ARID1A inactivating mutations in culture (PMID: 35852858).
|
35852858
|
|
ARID1A inact mut
|
melanoma
|
not predictive
|
unspecified immune checkpoint inhibitor
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1A, did not correlate with improved survival in 2 separate cohorts of patients with melanoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 1.70 (p=0.192, n=86) and 1.02 (p=0.939, n=192), respectively (PMID: 32321774).
|
32321774
|
|
ARID1A inact mut
|
transitional cell carcinoma
|
not predictive
|
unspecified immune checkpoint inhibitor
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1A, did not correlate with improved survival in 2 separate cohorts of patients with transitional cell carcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 1.44 (p=0.34, n=56) and 0.82 (p=0.559, n=93), respectively (PMID: 32321774).
|
32321774
|
|
ARID1A inact mut
|
lung non-small cell carcinoma
|
unknown
|
unspecified immune checkpoint inhibitor
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1A, correlated with worse survival in one cohort of patients with non-small cell lung cancer treated with systemic immune checkpoint inhibitors but not the other, with adjusted HRs for overall survival of 1.44 (p=0.018, n=334) and 1.84 (p=0.379, n=255), respectively (PMID: 32321774).
|
32321774
|
|
ARID1A inact mut
|
renal cell carcinoma
|
unknown
|
unspecified immune checkpoint inhibitor
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1A, correlated with improved survival in one cohort of patients with renal cell carcinoma treated with systemic immune checkpoint inhibitors but not the other, with adjusted HRs for overall survival of 0.33 (p=0.004, n=68) and 1.04 (p=0.906, n=118), respectively (PMID: 32321774).
|
32321774
|
|
ARID1A inact mut
|
head and neck squamous cell carcinoma
|
not predictive
|
unspecified immune checkpoint inhibitor
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1A, did not correlate with improved survival in 2 separate cohorts of patients with head and neck squamous cell carcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 0.74 (p=0.631, n=31) and 0.76 (p=0.622, n=68), respectively (PMID: 32321774).
|
32321774
|
|
ARID1A inact mut
|
colorectal adenocarcinoma
|
unknown
|
unspecified immune checkpoint inhibitor
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1A, correlated with improved survival in one cohort of patients with colorectal adenocarcinoma treated with systemic immune checkpoint inhibitors but not the other, with adjusted HRs for overall survival of 0.30 (p=0.03, n=35) and 0.56 (p=0.244, n=63), respectively (PMID: 32321774).
|
32321774
|
|
ARID1A inact mut
|
gastroesophageal adenocarcinoma
|
not predictive
|
unspecified immune checkpoint inhibitor
|
Clinical Study - Cohort |
Actionable |
In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1A, did not correlate with improved survival in 2 separate cohorts of patients with gastroesophageal adenocarcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 0.70 (p=0.403, n=66) and 0.46 (p=0.071, n=59), respectively (PMID: 32321774).
|
32321774
|
|
ARID1A inact mut
|
ovarian cancer
|
predicted - sensitive
|
HM97662
|
Preclinical |
Actionable |
In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of ovarian cancer harboring an ARID1A loss-of-function mutation (Cancer Res (2024) 84 (6_Supplement): 3240).
|
detail...
|
|
ARID1A inact mut
|
lung small cell carcinoma
|
predicted - sensitive
|
HM97662
|
Preclinical |
Actionable |
In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of small cell lung cancer harboring an ARID1A mutation (Cancer Res (2024) 84 (6_Supplement): 3240).
|
detail...
|
|
ARID1A inact mut
|
prostate cancer
|
predicted - sensitive
|
HM97662
|
Preclinical |
Actionable |
In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of prostate cancer harboring an ARID1A mutation (Cancer Res (2024) 84 (6_Supplement): 3240).
|
detail...
|
|
ARID1A inact mut
|
stomach cancer
|
predicted - sensitive
|
HM97662
|
Preclinical |
Actionable |
In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of gastric cancer harboring an ARID1A mutation (Cancer Res (2024) 84 (6_Supplement): 3240).
|
detail...
|
|
ARID1A inact mut
|
urinary bladder cancer
|
predicted - sensitive
|
HM97662
|
Preclinical |
Actionable |
In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of bladder cancer harboring an ARID1A loss-of-function mutation (Cancer Res (2024) 84 (6_Supplement): 3240).
|
detail...
|
|
ARID1A dec exp
|
urinary bladder cancer
|
sensitive
|
Dactolisib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Dactolisib (BEZ235) inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).
|
35852858
|
|
ARID1A dec exp
|
breast cancer
|
conflicting
|
Talazoparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, human mammary epithelial cells with knockdown of ARID1A demonstrated resistance to Talzenna (talazoparib) when compared to parental cells in culture (PMID: 29669295).
|
29669295
|
|
ARID1A dec exp
|
breast cancer
|
conflicting
|
Talazoparib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Talzenna (talazoparib) selectively inhibited growth and induced apoptosis in breast cancer cells with knock-down of ARID1A in culture, and inhibited tumor growth in ARID1A-deficient breast cancer cell line xenograft models (PMID: 26069190).
|
26069190
|
|
ARID1A dec exp
|
ovarian cancer
|
sensitive
|
Talazoparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Talzenna (talazoparib) in ovarian cancer cells in culture (PMID: 26069190).
|
26069190
|
|
ARID1A dec exp
|
urinary bladder cancer
|
sensitive
|
Alpelisib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Piqray (alpelisib) inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).
|
35852858
|
|
ARID1A dec exp
|
urinary bladder cancer
|
sensitive
|
Pictilisib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Pictilisib (GDC-0941) inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).
|
35852858
|
|
ARID1A dec exp
|
ovarian clear cell carcinoma
|
predicted - sensitive
|
Molibresib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Molibresib (GSK525762) in ovarian clear cell carcinoma cell lines in culture (PMID: 29760405).
|
29760405
|
|
ARID1A dec exp
|
breast cancer
|
sensitive
|
Olaparib
|
Preclinical |
Actionable |
In a preclinical study, Lynparza (olaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).
|
26069190
|
|
ARID1A dec exp
|
breast cancer
|
sensitive
|
Rucaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rubraca (rucaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).
|
26069190
|
|
ARID1A dec exp
|
breast cancer
|
sensitive
|
Veliparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Veliparib (ABT-888) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).
|
26069190
|
|
ARID1A dec exp
|
ovarian cancer
|
predicted - sensitive
|
APR-246
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with APR-246, demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770).
|
30686770
|
|
ARID1A dec exp
|
urinary bladder cancer
|
sensitive
|
Tazemetostat
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tazverik (tazemetostat) inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).
|
35852858
|
|
ARID1A dec exp
|
urinary bladder cancer
|
sensitive
|
CPI-1205
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, CPI-1205 inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).
|
35852858
|
|
ARID1A dec exp
|
ovarian cancer
|
sensitive
|
GSK126
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, GSK126 inhibited growth of ovarian cancer cells with knockdown of ARID1A expression in culture (PMID: 25686104).
|
25686104
|
|
ARID1A dec exp
|
urinary bladder cancer
|
sensitive
|
GSK126
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, GSK126 inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).
|
35852858
|
|
ARID1A dec exp
|
ovarian cancer
|
predicted - sensitive
|
Buthionine sulfoximine
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with Buthionine sulfoximine (BSO), demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770).
|
30686770
|
|
ARID1A dec exp
|
urinary bladder cancer
|
sensitive
|
MAK683
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, MAK683 inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).
|
35852858
|
|
ARID1A dec exp
|
urinary bladder cancer
|
sensitive
|
GSK126 + Pictilisib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of GSK126 and Pictilisib (GDC-0941) synergistically inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858).
|
35852858
|
|
ARID1A G1450fs
|
urinary bladder cancer
|
sensitive
|
Tulmimetostat
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A G1450fs in culture (PMID: 38833522).
|
38833522
|
|
ARID1A Q456*
|
colorectal cancer
|
sensitive
|
Talazoparib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Talzenna (talazoparib) inhibited colony formation and proliferation of a human colorectal cancer cell line harboring ARID1A Q456* in culture and inhibited tumor formation in colorectal cancer xenografts harboring ARID1A Q456* (PMID: 26069190).
|
26069190
|
|
ARID1A Q456*
|
colorectal cancer
|
sensitive
|
Dasatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a colorectal cancer cell line homozygously expressing ARID1A Q456* demonstrated sensitivity to treatment with Sprycel (dasatinib) in culture (PMID: 27364904).
|
27364904
|
|
ARID1A Q456*
|
colorectal cancer
|
sensitive
|
Olaparib
|
Preclinical |
Actionable |
In a preclinical study, Lynparza (olaparib) inhibited proliferation and colony formation of a colorectal cancer cell line harboring ARID1A Q456* in culture (PMID: 26069190).
|
26069190
|
|
ARID1A Q456*
|
colorectal cancer
|
sensitive
|
Rucaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Rubraca (rucaparib) treatment resulted in increased apoptosis of colorectal cancer cells harboring ARID1A Q456* in culture (PMID: 26069190).
|
26069190
|
|
ARID1A Q456*
|
colorectal cancer
|
sensitive
|
VE-821
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, colorectal cancer cells homozygous for ARID1A Q456* were sensitive to VE-821 in in vitro assays, demonstrating decrease cell survival (PMID: 27958275).
|
27958275
|
|
ARID1A Q456*
|
colorectal cancer
|
sensitive
|
Berzosertib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Berzosertib (VX-970) treatment in colorectal cancer cells homozygous for ARID1A Q456* resulted in decreased cell survival in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275).
|
27958275
|
|
ARID1A Q1148*
|
ovarian clear cell carcinoma
|
predicted - sensitive
|
JQ1
|
Preclinical - Pdx |
Actionable |
In a preclinical study, JQ1 inhibited tumor growth in an ovarian clear cell carcinoma patient-derived xenograft (PDX) model harboring ARID1A Q1148*, but did not inhibit growth in a model with wild-type ARID1A (PMID: 29760405).
|
29760405
|
|
ARID1A negative
|
ovarian clear cell carcinoma
|
predicted - sensitive
|
ENMD-2076
|
Phase II |
Actionable |
In a Phase II trial, ENMD-2076 treatment resulted a median progression-free survival (PFS) of 4.4 months in patients with ARIDA1A-negative recurrent ovarian clear cell carcinoma and a median PFS of 3.6 months in ARID1A-positive patients, with a statistically significant difference in estimated 6-month PFS rate (0.33 vs 0.12, p=0.023) (PMID: 30108107).
|
30108107
|
|
ARID1A del
|
stomach cancer
|
sensitive
|
Capivasertib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Truqap (capivasertib) inhibited proliferation and colony formation in an ARID1A knockout gastric cancer cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 39003371).
|
39003371
|
|
ARID1A Y788* ARID1A M1154fs
|
ovarian clear cell carcinoma
|
predicted - sensitive
|
Bevacizumab + Pembrolizumab
|
Case Reports/Case Series |
Actionable |
In a clinical case study, a patient with ovarian clear cell carcinoma harboring both ARID1A Y788* and M1154fs was sensitive to the combination therapy of Keytruda (pembrolizumab) and Avastin (bevacizumab), demonstrating a decrease in serum marker, tumor regression after 3 cycles, and complete remission after 9 cycles of treatment (PMID: 33292376).
|
33292376
|
|
ARID1A Y551Lfs*72 ARID1A Q758Rfs*75
|
ovarian cancer
|
sensitive
|
Olaparib + Temozolomide
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib) and Temodar (temozolomide) synergistically inhibited viability of an ovarian cancer cell line harboring ARID1A Y551Lfs*72 and Q758Rfs*75 in culture and inhibited tumor growth in a cell line xenograft model (PMID: 37306706).
|
37306706
|
|
ARID1A A35Gfs*76
|
cholangiocarcinoma
|
no benefit
|
Niraparib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, a cholangiocarcinoma patient-derived xenograft (PDX) cell line harboring ARID1A A35Gfs*76 was insensitive to Zejula (niraparib) in culture (PMID: 36374558).
|
36374558
|
|
ARID1A A35Gfs*76
|
cholangiocarcinoma
|
no benefit
|
Olaparib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, a cholangiocarcinoma patient-derived xenograft (PDX) cell line harboring ARID1A A35Gfs*76 was insensitive to Lynparza (olaparib) in culture (PMID: 36374558).
|
36374558
|
|
ARID1A A35Gfs*76
|
cholangiocarcinoma
|
no benefit
|
Pamiparib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, a cholangiocarcinoma patient-derived xenograft (PDX) cell line harboring ARID1A A35Gfs*76 was insensitive to Pamiparib (BGB-290) in culture (PMID: 36374558).
|
36374558
|
|
ARID1A Q586*
|
ovarian cancer
|
sensitive
|
Olaparib + Temozolomide
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib) and Temodar (temozolomide) inhibited viability of an ovarian cancer cell line harboring ARID1A Q586* in culture (PMID: 37306706).
|
37306706
|
|
ARID1A Q1835* ARID1A Q2115*
|
ovarian cancer
|
sensitive
|
Olaparib + Temozolomide
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib) and Temodar (temozolomide) synergistically inhibited viability of an ovarian cancer cell line harboring ARID1A Q1835* and Q2115* in culture and inhibited tumor growth in a cell line xenograft model (PMID: 37306706).
|
37306706
|
|
ARID1A Q2209Sfs*22
|
ovarian cancer
|
sensitive
|
Olaparib + Temozolomide
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib) and Temodar (temozolomide) inhibited viability of an ovarian cancer cell line harboring ARID1A Q2209Sfs*22 in culture (PMID: 37306706).
|
37306706
|
|
ARID1A P549fs ARID1A N756fs
|
ovarian clear cell carcinoma
|
sensitive
|
Tulmimetostat
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Tulmimetostat inhibited viability of an ovarian clear cell carcinoma cell line harboring ARID1A N756fs and P549fs in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38833522).
|
38833522
|
|
ARID1A S552*
|
urinary bladder cancer
|
sensitive
|
Tulmimetostat
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A S552* in culture (PMID: 38833522).
|
38833522
|
|
ARID1A S2256*
|
urinary bladder cancer
|
sensitive
|
Tulmimetostat
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A S2256* in culture (PMID: 38833522).
|
38833522
|
|
ARID1A Q1327*
|
pancreatic ductal adenocarcinoma
|
predicted - sensitive
|
Olaparib
|
Case Reports/Case Series |
Actionable |
In a clinical case study, Lynparza (olaparib) treatment resulted in an objective response with 40% decrease in the diameter of the lesion and a progression-free survival of at least 13 months in a patient with pancreatic ductal adenocarcinoma harboring ARID1A Q1327* along with KRAS G12R, TP53 R273C, and CBL A463V (PMID: 31764178).
|
31764178
|
